Prostate cancer, Version 2.2019: NCCN Clinical Practice Guidelines in Oncology Guidelines
| Authors: | Mohler, J. L.; Antonarakis, E. S.; Armstrong, A. J.; D'Amico, A. V.; Davis, B. J.; Dorff, T.; Eastham, J. A.; Enke, C. A.; Farrington, T. A.; Higano, C. S.; Horwitz, E. M.; Hurwitz, M.; Ippolito, J. E.; Kane, C. J.; Kuettel, M. R.; Lang, J. M.; McKenney, J.; Netto, G.; Penson, D. F.; Plimack, E. R.; Pow-Sang, J. M.; Pugh, T. J.; Richey, S.; Roach, M. 3rd; Rosenfeld, S.; Schaeffer, E.; Shabsigh, A.; Small, E. J.; Spratt, D. E.; Srinivas, S.; Tward, J.; Shead, D. A.; Freedman-Cass, D. A. |
| Title: | Prostate cancer, Version 2.2019: NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 17 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2019-05-01 |
| Start Page: | 479 |
| End Page: | 505 |
| Language: | English |
| DOI: | 10.6004/jnccn.2019.0023 |
| PUBMED: | 31085757 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
